
Baxter (BAX) Stock Forecast & Price Target
Baxter (BAX) Analyst Ratings
Bulls say
Baxter International's Healthcare Systems & Technologies segment experienced notable year-over-year sales growth, with increases of approximately 6% and 2% in the first two quarters of 2025, alongside projected growth of around 4% and 2% for the subsequent quarters. The company has benefited from effective pricing initiatives that are expected to yield an approximate 100 basis points contribution to sales growth for both 2024 and 2025. Additionally, the strategic acquisition of Hillrom has enhanced Baxter's product offerings, positioning the company to capture further market opportunities in the healthcare sector.
Bears say
Baxter International experienced a disappointing performance in the second quarter of 2025, with sales, margins, and earnings per share (EPS) all falling below consensus expectations. This underperformance stems from ongoing operational challenges that persisted throughout 2021-2023, characterized by both external pressures and internal missteps, which have resulted in mixed quarterly results and negative guidance revisions. Additionally, the company reported gross margins of 40.7% and operating margins of 15.1%, both of which were significantly below consensus estimates, driven by sales softness and manufacturing inefficiencies.
This aggregate rating is based on analysts' research of Baxter and is not a guaranteed prediction by Public.com or investment advice.
Baxter (BAX) Analyst Forecast & Price Prediction
Start investing in Baxter (BAX)
Order type
Buy in
Order amount
Est. shares
0 shares